[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Paul Strauss\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":456},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,38,68,84,104,127,153,170,192,216,235,259,278,295,314,340,365,386,410,434],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100498609",false,"NCT05772481","Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma","TEPIREC","Inclusion Criteria:\n\n* World Health Organization (WHO)\u002FEastern Cooperative Oncology Group (ECOG) 0 to 2\n* Histologically proven rectal cancer\n* clinical tumor classification (cT) : cT3 - cT4 or all T \u002F N+ \u002F M0\n* Tumor resectable or considered resectable after chemoradiotherapy\n* Decision chemotherapy followed by neoadjuvant chemoradiotherapy decided at the organ Multidisciplinary Meeting\n* Absence of distant metastases\n* Adequate contraception for women of childbearing potential\n* Free, signed and informed consent\n* For women of childbearing potential : negative pregnancy test\n\nExclusion Criteria:\n\n* Subject with Uncontrolled diabetes\n* Contraindication to surgery\n* Contraindication to MRI\n* Contraindication to PET scan\n* Contraindication to chemotherapy\n* History of pelvic radiotherapy\n* History of major co-morbidity that may prevent treatment and no active infection (HIV or chronic hepatitis B or C)\n* Colloid (mucinous) adenocarcinoma\n* Presence of distant metastases\n* Contraindication to 5-FluoroUracil (FU), oxaliplatin or irinotecan\n* History of known Gilbert's disease\n* Patient with known UGT1A1 genotype\n* Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency\n* Medical history of chronic diarrhea or inflammatory disease of the colon or rectum\n* Medical history of angina or myocardial infarction.\n* Active progressive infection or any other serious medical condition that could compromise the administration of the treatment\n* Other concurrent cancer, or medical history of cancer other than treated in situ cervical carcinoma or basal cell carcinoma or squamous cell carcinoma\n* Patient enrolled in another clinical trial testing an investigational agent\n* Pregnant or breastfeeding woman\n* Persons deprived of their freedom or under guardianship or incapable of giving consent\n* Any psychological, familial, sociological or geographic condition that may interfere with the study protocol or follow-up schedule","ALL","18 Years","75 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","With 50 patients included, this trial would be the largest pilot study evaluating the value of MRI PET in locally advanced rectal cancer. On the other hand, it would be the only pilot study performing several MRI PET during neoadjuvant treatment. Presumably, the response assessed at the 2nd MRI PET (before cycle 4 or induction chemotherapy) would be predictive of the overall response at the end of neoadjuvant treatment. Then, it would be possible to predict precociously the tumor response.",[24],"Rectal Cancer","RECRUITING","2026-06-16",{"date":28,"type":29},"2026-06-17","ACTUAL",{"date":31,"type":29},"2023-05-19",{"date":33,"type":20},"2030-07-25",{"name":35,"class":36},"Centre Paul Strauss","OTHER",1,{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":37},"100551317","NCT06458517","Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers","Pilot Observational Study of Transcutaneous and Intraoral Photobiomodulation in the Prevention and Treatment of Radiomucositis in Head and Neck Cancers Treated by Radiotherapy - RADIO-PBM Trial","RADIO-PBM","Inclusion Criteria:\n\n* Adult patient (18 years old and older);\n* Patients with oral cavity or oropharynx cancer treated with radiotherapy or chemo-radiotherapy;\n* Karnofsky Performance Status \\> 60%;\n* Able to understand French;\n* With signed informed consent;\n* Affiliated to French Health Security Insurance\n\nExclusion Criteria:\n\n* Allergy to polyurethanes;\n* Head and Neck tumors that are localized to other sites than oral cavity or oropharynx\n* Previous irradiation of Head and Neck (whatever the time lapse between the two irradiations)\n* Pregnant and breastfeeding woman;\n* Patients with pacemaker device\n* Epileptic patients;\n* Concomitant treatment or treatment within the 7 days before inclusion with one of several drugs from the following list: fluoroquinolones, cycline, methotrexate, auranofin\n* Patients with ophthalmic diseases (such as maculopathy, retinopathy, glaucoma and cataract, retinal damage)\n* Patients under judicial protection",{"count":46,"type":20},60,"INTERVENTIONAL",[49],"NA","The aim of this feasibility, prospective, single-center trial is to compare an intra-oral Photobiomodulation (PBM) via the Caremin650TM device (NeoMedLight) and a transcutaneous PBM via the ATP 38® device (Swiss Bio Innov) in patients treated with radiotherapy or chemoradiotherapy for cancer of the oropharynx or oral cavity. PBM session will be carried out first at the rate of two sessions per week for preventive purposes, and then, in case of occurence of grade 1 mucositis, three sessions per week with curative purpose.",[52],"Head and Neck Neoplasms",[54,55,56,57,58],"Radiotherapy","Chemotherapy","Photobiomodulation therapy","Low-level laser therapy","Oral mucositis","NOT_YET_RECRUITING","2026-06-04",{"date":62,"type":29},"2026-06-05",{"date":64,"type":20},"2026-06-15",{"date":66,"type":20},"2029-11-15",{"name":35,"class":36},{"id":69,"slug":4,"hasResults":10,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":37},"100464463","NCT05328024","Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma","IPRICE","Inclusion Criteria:\n\n* Patients with recurrent squamous-cell carcinoma of the head and neck not amenable to local therapy and\u002For with metastatic disease\n* Tumor directly accessible to clinical examination (tumor of oral cavity and of oropharynx) and\u002For cervical lymphadenopathy accessible to echography allowing to realise biopsy under local anesthesia\n* Indication to treatment by anti-PD1 immunotherapy according to French competent authority recommendations\n* Performance status 0, 1 or 2\n* At least one measurable lesion on RECIST V1.1 criteria\n\nExclusion Criteria:\n\n* Head and neck squamous cell carcinoma accessible to a local treatment\n* Cancer of nasopharynx, sinus or nasal cavity\n* Other histology than epidermoid\n* Patients with contraindication for anti-PD1 immunotherapy",{"count":46,"type":20},"This project aims to organise the sampling of blood and tumor at key points of the standard of care of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC). This will allow to identify new potential predictive biomarkers of efficacy of immunotherapy and to investigate the evolution of the tumoral microenvironment after successive systemic treatments.",[77],"Head and Neck Cancer",{"date":62,"type":29},{"date":80,"type":29},"2023-08-25",{"date":82,"type":20},"2029-08-25",{"name":35,"class":36},{"id":85,"slug":4,"hasResults":10,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":47,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":37},"100639354","NCT07628257","Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up","Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of Diffusion Tensor Imaging (DTI) and Resting State Functional MRI (Rs-fMRI) to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up","GlioConnect","Inclusion Criteria:\n\n* Adult patients\n* Patients with glioblastoma\n* Patients treated in the Nuclear Medicine \\& Molecular Imaging Department of the Strauss Institute for PET\u002FMRI scans for:\n\n  * Preoperative metabolic evaluation of a brain-expanding lesion\n\nExclusion Criteria:\n\n* Contraindications to MRI\n* Minor or incapacitated adult\n* Patient deprived of liberty\n* Patient under legal guardianship\n* Patient unable to consent\n* Pregnant or breastfeeding woman",{"count":92,"type":20},80,[49],"The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms.\n\nThis approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.",[96],"Glioblastoma","2026-06-03",{"date":60,"type":29},{"date":100,"type":20},"2026-09-15",{"date":102,"type":20},"2030-09-15",{"name":35,"class":36},{"id":105,"slug":4,"hasResults":10,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":10,"sex":110,"minAge":16,"maxAge":4,"enrollmentInfo":111,"targetDuration":112,"studyType":21,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100608667","NCT07204535","Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy","TRUST-GB","Inclusion Criteria:\n\n* Confirmed diagnosis of cervical cancer with an indication for High-dose rate (HDR) or pulse-dose rate (PDR) uterovaginal brachytherapy;\n* Squamous cell carcinoma or other histological types;\n* WHO ≤ 2;\n* Ability to complete validated questionnaires in French;\n* Informed consent to participate in the study;\n* Patients over 18 years old\n\nExclusion Criteria:\n\n* Inability to understand or respond to questionnaires due to a cognitive disorder, intellectual disability, language barrier, or psychiatric disorder that impairs judgment;\n* Patient under juridic protection;\n* Pregnant or breastfeeding woman","FEMALE",{"count":92,"type":20},"60 Months","This is a multicenter, prospective study aimed at providing information on the psychological effects (including post-traumatic stress symptoms) of utero-vaginal brachytherapy in patients with cervical cancer using self-administered questionnaires. The study also aims to assess the persistence of these symptoms over time, up to 5 years after brachytherapy. The results could help identify patients at risk of post-traumatic stress in this context and develop appropriate psychological interventions to improve their psychological well-being during and after treatment.",[115],"Uterine Cervical Neoplasms",[117,118,119],"Brachytherapy","Post-TRaUmatic STress Disorder","Cervical cancer",{"date":60,"type":29},{"date":122,"type":29},"2025-11-17",{"date":124,"type":20},"2031-11-17",{"name":35,"class":36},2,{"id":128,"slug":4,"hasResults":10,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":47,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":126},"100552716","NCT06476704","Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","Phase 2 Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","PRACTISS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Localized or locally advanced soft tissue sarcoma of extremity proven by biopsy histological grade 2 and 3.\n* Pathological expert proof-reading in reference centers\n* HFRT and surgery planned (regardless the potential inclusion in this trial) as decided in a multidisciplinary tumor board, in reference centre (European Society for Medical Oncology (ESMO) guideline 2021)\n* R0 surgery is feasible, in reference centers\n* Pre-biopsy MRI available\n* Performance status of 0-2 and life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Patient who cannot undergo MRI\n* Patients with localized or locally advanced soft tissue sarcoma of extremity proven by biopsy with histological grade 1\n* Previous radiation in the area\n* Woman who is pregnant or breastfeeding\n* Soft tissue sarcoma developed in irradiated area.\n* Patients with myxoid liposarcoma, embryonal or alveolar rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, angiosarcoma, primitive neuroectodermal tumor, desmoid-type fibromatosis, or dermatofibrosarcoma protuberans\n* Patient with metastatic disease, other concomitant cancer or history of cancer treated and controlled within the previous 3 years.",{"count":135,"type":20},42,[137],"PHASE2","This is phase II randomized, multicenter study of treatment with L-TC and preoperative HFRT in patients who were aged 18 years or older with documented localised or locally advanced soft-tissue sarcoma of the extremity.\n\nEligible patients will be randomly assigned 2:1 to receive a preoperative HFRT alone (Arm A) or L-TC with preoperative HFRT (Arm B).",[140],"Sarcoma",[142,143,144,145,146],"hypofractionated radiotherapy","soft tissue sarcoma","hypoxia","liposomal transcrocetin","neo-adjuvant",{"date":60,"type":29},{"date":149,"type":20},"2026-07-01",{"date":151,"type":20},"2033-06-01",{"name":35,"class":36},{"id":154,"slug":4,"hasResults":10,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":10,"sex":110,"minAge":16,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":37},"100411530","NCT04638725","Identification of Genetic Determinants for Treatment Resistance\u002FSensitivity and\u002For Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer","SIGHER","For inclusion in the study, patients must be affiliated to the national or local social security, and must meet all the following criteria:\n\nInclusion Criteria:\n\n* Age ≥ 18 years\n* Histological diagnosis of breast adenocarcinoma. Non-metastatic and operable.\n* Current or prior treatment with one therapy targeting HER2 in adjuvant or neoadjuvant phase for the current breast cancer\n* Given written informed consent\n\nExclusion Criteria:\n\n* Patients not able to comply to the protocol assessments for geographic, social or psychological reasons\n* Patients placed under judicial protection, guardianship, or supervision\n* History of cancer in the 5 years preceding anti-HER2 therapy initiation\n* Concomitant cancer (except for an other non metastatic cancer treated only with surgery)\n\nNote : Patients are eligible at any time of the follow-up if the adjuvant or neoadjuvant chemotherapy started after 01\u002F01\u002F2019. Patients treated with trastuzumab, pertuzumab, neratinib or T-DM1 in a clinical trial are eligible in the SIGHER study.",{"count":160,"type":20},9000,"This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify constitutional genetic factors associated with histological response, resistance or sensibility to treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 9000 patients will be enrolled in this study. Blood samples will be collected after informed consent and inclusion in the study. Patients will be treated and followed according to the standards of their treating center. They will be followed every six months for five years.",[163],"HER2-positive Breast Cancer",{"date":60,"type":29},{"date":166,"type":29},"2021-12-15",{"date":168,"type":20},"2033-12-15",{"name":35,"class":36},{"id":171,"slug":4,"hasResults":10,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},"100530894","NCT06192719","EULAT Eradicate GBC","Establishment and Exploitation of a European-Latin American Research Consortium Towards Eradication of Preventable Gallbladder Cancer - EULAT Eradicate GBC","EULAT","Inclusion Criteria:\n\n1. Cohort A. Patients with gallbladder cancer or dysplasia, both before and after the start of their anticancer treatment.\n\n   Cohort B. Patients with cholelithiasis before cholecystectomy (only patients scheduled for cholecystectomy will be recruited)\n2. Diagnosis confirmed in accordance with standard protocols of the participating hospitals\n3. Men and women aged 18 or over\n\nExclusion Criteria:\n\n1. Any medical condition that present an unreasonable risk to the participant.\n2. Any psychiatric condition that interferes with understanding informed consent.",{"count":178,"type":20},15000,"Gallstones are relatively frequent in women and constitute one of the main risk factors for gallbladder cancer (GBC).\n\nCurrently, GBC diagnosis is mainly based on imaging (ultrasound or abdominal CT) associated with invasive examinations (biopsy and surgery), with no marker available to date to accurately predict risk and diagnose the disease early. The only curative treatment for GBC remains surgery with complete resection of tumors in early stages.\n\nGiven the aggressiveness of GBC and the very limited therapeutic options, as well as the possibility of preventing GBC by cholecystectomy during the 10 to 20 years required for the development of gallbladder tumors, it is imperative to develop effective and efficient prevention strategies based on a prioritization of interventions according to environmental and genetic-molecular risk factors.\n\nThe investigators aim to identify epidemiological factors linked to the development of GBC, and to identify, validate and functionally characterize genetic-molecular markers in blood, saliva, urine, bile and stool that allow risk prediction, early diagnosis and precision treatment of incidental tumors.",[181,182],"Gallbladder Cancer","Gallstone Disease","2026-02-16",{"date":185,"type":29},"2026-02-18",{"date":187,"type":29},"2019-12-01",{"date":189,"type":20},"2028-12-31",{"name":35,"class":36},36,{"id":193,"slug":4,"hasResults":10,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":37},"100550174","NCT06443645","Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B","Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis - SCARA-B","SCARA-B","Inclusion Criteria:\n\n* Patient \\> 18 years old\n* Diagnosed with localized breast cancer\n* Indication for first-line surgery or anthracycline-based chemotherapy.\n\nExclusion Criteria:\n\n* History of chemotherapy or targeted therapy or immunotherapy administered before inclusion\n* Patient currently being treated with anti-SGLT2, conversion enzyme inhibitor or ARA2\n* Patient with known heart disease (ischemic, rhythmic, valvular, etc.)\n* Patient with a Glomerular filtration rate \\\u003C 45 mL\u002Fmin\u002F1.73m² according to the pre-therapeutic assessment\n* Patient with impaired liver function\n* Patient who is pregnant or breastfeeding\n* Patient with a second cancer undergoing treatment\n* Patient under guardianship or curatorship, protection of justice or deprived of liberty",{"count":19,"type":20},"In the context of breast cancer, in case of an indication for chemotherapy, anthracycline-based protocols make it possible to improve the overall survival of patients most at risk. The frequency of anthracycline-related cardiac toxicities (ARCT) increases with the cumulative dose of anthracyclines administered and explains, at least in part, the increased risk of cardiovascular (CV) mortality in patient populations treated for breast cancer. The numerous indications for anthracycline-based protocols have made it possible to describe ARCT, among which heart failure with reduced left ventricular ejection fraction (LVEF) remains one of the most comorbid. In addition to left ventricular dysfunction, anthracyclines have been associated with endothelial dysfunction, microvascular damage and myocardial ischemia responsible for dilated cardiomyopathy.\n\nDifferent approaches have attempted to better understand and prevent these ARCT. However, apart from the notion of limit cumulative doses of anthracyclines, few of them have made it possible to screen patients at risk and prevent the onset of cardiac dysfunction. The search for biological markers (Troponin I, BNP) or ultrasound markers (Longitudinal Strain) warning of subclinical cardiac damage is still struggling to assert its interest due in particular to significant inter- and intra-observer variability. Therapeutically, ACE inhibitors and beta-blockers have shown a significant improvement in the incidence rate of LVEF reduction during adjuvant treatment of breast cancer. However, despite equivalent signals in other cancers, the studies conducted to date are insufficiently powered and the role of these treatments is limited to secondary prevention or the treatment of objective heart failure. It remains necessary to determine new biological markers that can identify patients most at risk of ARCT and thus adapt our therapeutic prevention strategies. To do this, it is first necessary to better understand the pathophysiology underlying these ARCT.\n\nThe objective of this study is to determine whether expression of the receptor among endothelium and circulating cells, SGLT2, is associated with an additional risk of presenting cardiovascular toxicity following treatment with anthracycline. If this association is demonstrated, it will then be possible to better screen and prevent these cardiovascular complications.",[202],"Breast Neoplasms",[204,205,206,207],"Breast cancer","Cardiotoxicities","SGLT2","Anthracyclines","2026-02-02",{"date":210,"type":29},"2026-02-04",{"date":212,"type":29},"2025-02-17",{"date":214,"type":20},"2026-12",{"name":35,"class":36},{"id":217,"slug":4,"hasResults":10,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":47,"phases":224,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":126},"100489478","NCT05653635","Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study","ReciDOPA","Inclusion Criteria:\n\n* Age \\> 18 years\n* Glioblastoma, World Health Organization (WHO) grade IV, histologically proven\n* Performance status 0, 1 or 2\n* Neurological status ≥ 2\n* Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm)\n* Radiological proven recurrence according to 1 and 2 criteria, Wen et al\n* Remaining node after partial surgery post-recurrence\n* 1 to 3 recurrence site(s) \\\u003C 35 mm in wide axis and separated by at least 5 mm\n* Volume of each lesion \\\u003C 35 mL\n* Distance between recurrence node(s) and optic nerves (left and right), chiasma and\u002For cerebral trunk \\> 10 mm\n\nExclusion Criteria:\n\n* Patient with contraindication to MRI or PET\n* Glioblastomatose\n* Pregnancy or breastfeeding\n* Patient that do not understand French\n* Patient without affiliation to the national or local social security\n* Patients not able to comply to the protocol assessments for geographic, social or psychological reasons\n* Minor or patients placed under guardianship or supervision\n* Patients deprived of liberty\n* Patients placed under judicial protection\n* Patients that are not able to express their consent",{"count":223,"type":20},54,[137],"ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.",[96],[96,228],"Simultaneous Integrated Boost",{"date":210,"type":29},{"date":231,"type":20},"2026-03-01",{"date":233,"type":20},"2028-09-01",{"name":35,"class":36},{"id":236,"slug":4,"hasResults":10,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":47,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},"100489477","NCT05653622","Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma","Simultaneous Integrated Boost FDOPA PET Guided in Patients With Partially- or Non-operated Glioblastoma","SIB-DOPA","Inclusion Criteria:\n\n* Unfit patient without indication to the STUPP protocol :\n\nCohort 1 : Non-operable patients and ≥ 18 years old or ≤ 70 years old and Karnofsky Index (KI) ≥ 50% on inclusion AND Result of a biopsy available Cohort 2 : Patients \\> 70 years old and Balducci score I or II and KI ≥ 60% on inclusion AND Partial resection (defined on the remnographic criteria of postoperative MRI) OR biopsy result available\n\n* Histologically proven glioblastoma\n* Increased metabolism of amino acids in PET FDOPA allowing contouring the Biological Target Volume (BTV)\n\nExclusion Criteria:\n\n* Patients with an indication for irradiation according to the STUPP protocol (fit patient)\n* Patient with a contraindication to MRI or PET\n* Limit of the provisional target volume or Planning target volume (PTV), second PTV \\\u003C 2 cm from the chiasm and the optic nerves\n* Absence of uptake of FDopa",{"count":243,"type":20},75,[137],"Glioblastoma (GBM) is the most common primary brain cancer in adults. Surgery, chemoradiotherapy (temozolomide TMZ) and then adjuvant TMZ is the standard treatment. But, most patients relapse in a median time of 8-9 months; the median overall survival (OS) ranged from 15 to 18 months.\n\nSome frail patients received hypofractionated radiation and concomitant and adjuvant TMZ. For some, the radiation dose is not optimal. Moreover, recurrences develop mainly in the initial tumor site. These two reasons justify increasing the dose. To limit the movements of these fragile patients, the method consists of increasing the dose without increasing the number of sessions by using the Simultaneous Integrated Boost (SIB) which increases the dose in targeted volumes while the rest of the volume receives a minimum dose. A phase I trial showed the possibility of increasing the dose in SIB up to 80 Gy in a part of the GBM enhanced on MRI.\n\nFDOPA PET detects certain more aggressive tumor areas, areas likely to recur. Integrating them into the SIB seems appropriate. A phase II trial showed the interest of SIB guided by FDOPA PET in terms of progression-free survival but without impact on OS. This study differed from the one the investigators propose, because a dose and conventional fractionation, identical to that of the European Organization for Research and Treatment of Cancer\u002FNational Cancer Information Center (NCIC\u002FEORTC) protocol were delivered, the gliomas were unmethylated MGMT, less likely to respond. Studies with SIB and hypofractionation are often retrospective and for others, hypofractionation was debatable and the dose increase was not based on PET capture but on MRI. However, a prospective phase II study, with SIB and hypofractionation, not integrating FDopa PET has demonstrated the relevance of SIB.\n\nIn this project, the investigators propose to use the integrated boost technique (SIB) guided by PET FDOPA to increase the radiation dose in GBM, in patients either fragile and partially operated, or only biopsied and for whom the prognosis is the most pejorative.",[247],"Glioblastoma Multiforme, Adult",[249,250,251],"glioblastoma","intensity modulated radiation therapy","18F-DOPA-PET imaging",{"date":210,"type":29},{"date":254,"type":29},"2025-06-23",{"date":256,"type":20},"2029-07-01",{"name":35,"class":36},3,{"id":260,"slug":4,"hasResults":10,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":10,"sex":110,"minAge":16,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":47,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":126},"100551116","NCT06455904","Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study","PROTECT-07","Inclusion Criteria:\n\n* Woman ≥ 18 years old\n* Stage I to III breast cancer\n* Patient currently planning (neo)adjuvant treatment combining anthracycline-cyclophosphamide and weekly paclitaxel (± trastuzumab)\n* Affiliation to a social security system\n* Able to speak, read and understand French\n\nExclusion Criteria:\n\n* No prior chemotherapy treatment\n* Any known cardiac or vascular pathology\n* Contraindications to physical fitness assessment\n* Protected adult\n* Psychiatric, musculoskeletal or neurological problems\n* Pregnant or breastfeeding woman (NB: this population is already subject to a contraindication to (neo)adjuvant treatment. For women of childbearing age, a betaHCG dosage is already carried out systematically before the start of chemotherapy and information on the need for contraception throughout the chemotherapy period is provided before the start of treatment. As part of this study, only the presence of this test with a negative result at the start of chemotherapy will be checked. inclusion, if available).",{"count":266,"type":20},156,[49],"The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.",[270],"Breast Cancer","2026-01-29",{"date":208,"type":29},{"date":274,"type":29},"2024-05-30",{"date":276,"type":20},"2027-01-13",{"name":35,"class":36},{"id":279,"slug":4,"hasResults":10,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":10,"sex":110,"minAge":16,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":37},"100522475","NCT06083103","Contribution of PET\u002FMRI in Locally Advanced Cervical Cancer (ATICC)","Contribution of PET\u002FMRI in Locally Advanced Cervical Cancer","ATICC","Inclusion Criteria:\n\n* Patients aged from 18 years old and over\n* Patients with presumed cervical cancer of stages IB2 to IVA based on clinical data and pelvic MRI, undergoing pre-treatment assessment.\n* For women of childbearing potential : Adequate contraception throughout study participation.\n\nNote : enrollment in a concomitant clinical trial is authorized\n\nExclusion Criteria:\n\n* Oncological history that could possibly interfere with imaging results interpretation, apart from cervical cancer\n* Extra-nodal metastasis clinically or radiologically proven before study participation\n* Contraindication to MRI or injection of contrast agents containing gadolinium\n* Contraindication to lumbo-aortic lymphadenectomy\n* Persons deprived of liberty\n* Minor or patients placed under guardianship or supervision\n* Patient under judicial protection\n* Patient unable to consent",{"count":19,"type":20},"\\[18 F\\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET\u002FMRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge.\n\nPreviously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET\u002FCT (positron emission tomography\u002Fcomputed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.",[288],"Cervical Cancer",{"date":208,"type":29},{"date":291,"type":29},"2023-10-12",{"date":293,"type":20},"2026-09-11",{"name":35,"class":36},{"id":296,"slug":4,"hasResults":10,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":47,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":37},"100474983","NCT05464992","Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET\u002FMRI","GlioCEST","Inclusion Criteria:\n\nPatients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET\u002FMRI exam dedicated to:\n\n* Preoperative evaluation of a cerebral expansion lesion\n* Evaluation of glioma recurrences\n* Evaluation of brain metastases\n* Evaluation of recurrence of metastases\n\nExclusion Criteria:\n\n* Contraindication to the realization of an MRI\n* Minor or patients placed under guardianship or supervision\n* Patients deprived of liberty\n* Patients placed under judicial protection\n* Patients that are not able to express their consent\n* Pregnant and breastfeeding women",{"count":302,"type":20},800,[49],"Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. However, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions.\n\nChemical exchange saturation transfer (CEST) allow to overcome some limitations of proton magnetic resonance spectroscopy (1H-MRS) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. Moreover, CEST technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.",[306,307],"Glioma","Brain Metastases",{"date":208,"type":29},{"date":310,"type":29},"2022-12-28",{"date":312,"type":20},"2036-12-28",{"name":35,"class":36},{"id":315,"slug":4,"hasResults":10,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":320,"sex":110,"minAge":16,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":47,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":37},"100598307","NCT07069790","Effects of Chemotherapy Treatment on Metaboreflex, Mechanoreflex, and Baroreflex Function: PROTECT-08B Study","PROTECT-08B","Inclusion Criteria:\n\nPatient group :\n\n* Stage I to III breast cancer\n* Having completed (neo)adjuvant chemotherapy treatment less than three weeks ago\n\nControl group :\n\n\\- healthy women (no history of cancer) of similar age, weight, and physical activity level\n\nExclusion Criteria:\n\n* History of cancer\n* Any known chronic pathology\n* Protected minor or adult\n* Psychiatric, musculoskeletal or neurological problems\n* Implantation of a pacemaker\n* Pregnant woman\n* Presenting at least one contraindication to the use of transient blood flow occlusion",true,{"count":322,"type":20},24,[49],"Breast cancer is the most common cancer worldwide, with over 2.2 million new cases diagnosed in 2020. Treatments such as chemotherapy often lead to a reduced exercise capacity, mainly due to cardiovascular and neuromuscular dysfunctions. This decline appears to be primarily caused by increased central fatigue, while peripheral fatigue remains unchanged. This imbalance suggests a hyperactivation of type III-IV afferent nerve fibers, which are involved in the metaboreflex-a mechanism that significantly influences cardiovascular responses during exercise. Two non-invasive methods, post-exercise circulatory occlusion (PECO) and passive leg movement (PLM), will be used to assess this hyperactivity in patients. Additionally, baroreflex function-crucial for regulating blood pressure-will be evaluated using a direct method to determine its sensitivity and reactivity. By comparing patients with healthy controls under submaximal stimuli, this study aims to better understand chemotherapy-induced cardiovascular dysfunctions. Ultimately, the goal is to design personalized exercise programs to restore cardiovascular function and reduce treatment-related side effects.",[326],"Breast Adenocarcinoma",[328,329,330,331],"breast cancer","fatigue","muscle","heart","2025-12-30",{"date":334,"type":29},"2025-12-31",{"date":336,"type":29},"2025-10-02",{"date":338,"type":20},"2026-10-02",{"name":35,"class":36},{"id":341,"slug":4,"hasResults":10,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":10,"sex":15,"minAge":17,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":47,"phases":349,"briefSummary":350,"conditions":351,"keywords":354,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":37},"100444339","NCT05066139","Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)","Monocentric Randomized Study Evaluating the Impact of an Early Multidisciplinary Program in Elderly Subjects Starting a Chemotherapy for Digestive Cancer: Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)","EPODIG-G","Inclusion Criteria:\n\n* Patients must be ≥ 75 years old\n* Performance status 0, 1 or 2\n* Diagnostic of digestive cancer, all stages (adjuvant or metastatic), with an indication for chemotherapy treatment or targeted therapy for a treatment period of 24 weeks or more\n* Patients previously treated with one or several lines of chemotherapy for this digestive cancer are eligible\n* Estimated life expectancy ≥ 3 months\n* Patients able to speak, read and understand French\n* Signed informed consent from the patient\n* Patients must have a social security coverage\n\nExclusion Criteria:\n\n* History of differentiated neuroendocrine tumors grade 1 or 2 (pancreas, small intestine)\n* Cancer currently being treated (except for hormone therapy) other than current digestive cancer\n* History of major surgery and\u002For curative radiation therapy during the last 4 weeks before inclusion\n* Patients unable to submit to medical follow-up for geographical, social or psychological reasons\n* Patients placed under guardianship",{"count":348,"type":20},144,[49],"This is a monocentric, comparative, open-label, randomized parallel group study enrolling elderly subjects hospitalized in Strasbourg Europe Cancerology Institute (ICANS), starting chemotherapy or targeted therapy for the treatment of digestive cancer.",[352,353],"Digestive System Disease","Neoplasms",[355,356,357],"Digestive cancer","supportive care","gastrointestinal cancer",{"date":359,"type":29},"2026-01-05",{"date":361,"type":29},"2021-09-17",{"date":363,"type":20},"2030-10-17",{"name":35,"class":36},{"id":366,"slug":4,"hasResults":10,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":47,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":385},"100571831","NCT06725368","Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +\u002F- First-line Chemotherapy in Recurrent\u002FMetastatic Squamous Cell Carcinoma of the Head and Neck","Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +\u002F- First-line Chemotherapy in Recurrent\u002FMetastatic Squamous Cell Carcinoma of the Head and Neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO Immuno-oncology)","CARPACCIO","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years at inclusion\n2. Cytological or histological confirmation of the diagnosis of invasive squamous cell carcinoma of the head and neck\n3. One of the following locations: oral cavity, oropharynx (known p16 status), larynx or hypopharynx\n4. Cancers of unknown primary (CUP) of the head and neck are accepted\n5. Metastatic (stage IVc) or recurrent disease in patients ineligible for curative surgical treatment or radiotherapy\n6. Indication of a 2nd line after pembrolizumab +\u002F- chemotherapy\n7. Chemotherapy-free interval ≥ 3 months\n8. ECOG Performance Index (Performance Index) of 0, 1 or 2\n9. Patient with a life expectancy of at least 12 weeks\n10. Documented progression of a measurable tumor target according to RECIST 1.1\n11. Correct biology\n12. Patient (male or female of childbearing potential) using a highly effective contraceptive method\n13. Willingness and ability to comply with the visit schedule, treatment regimens, examinations and other procedures planned in the study\n14. Patient enrolled in a health insurance plan or beneficiary of such a plan\n15. Signed informed consent obtained before inclusion (after giving clear, fair and appropriate information)\n\nExclusion Criteria:\n\n1. Other histology\n2. Nasal, paranasal and nasopharyngeal cavities\n3. Symptomatic or active brain parenchymal metastases or leptomeningeal tumors\n4. Grade ≥2 neuropathy\n5. Patients may have previously received radiotherapy. A minimum period of 2 weeks is necessary between palliative or analgesic radiotherapy and the start of treatment\n6. Clinically significant heart disease or congestive heart failure NYHA (New York Heart Association) class 2 or greater. Patients must not have had unstable angina (symptoms of angina at rest) or new angina in the last 3 months or myocardial infarction in the last 6 months.\n7. History of other primary malignancies, except curatively treated malignancies with no evidence of recurrence, within 3 years before the first dose of treatment and a low potential risk of recurrence or non-recurrent skin cancer. melanoma or lentigo maligna properly treated without evidence of disease or carcinoma in situ adequately treated without evidence of disease. A history of T1 grade bladder cancer or T1 grade kidney cancer is accepted. Cervical carcinoma in situ or breast cancer in situ are accepted. Patients with papillary thyroid carcinoma, basal cell skin carcinoma are accepted. A history of prostate cancer is allowed if it is less than or equal to stage T2N0M0 and a Gleason score of 6.\n8. Known hypersensitivity to the active substance or excipient of the treatments under study\n9. Any uncontrolled intercurrent pathology\n10. Any psychiatric illness\u002Fsocial situation that may limit compliance with study procedures or prevent the patient from giving written informed consent\n11. Any chemotherapy or radiotherapy performed within 4 weeks of the first dose of study drug, except palliative radiotherapy to a non-target lesion\n12. Major surgery within 4 weeks before the first administration of treatment. Local palliative surgery for isolated lesions is tolerated\n13. Phenytoin prescribed for prophylaxis\n14. Administration of a live attenuated vaccine within 30 days before the first administration of study treatment, as well as during the duration of study treatment and up to 6 months after the last dose of treatment\n15. Participation in another clinical trial of an investigational treatment during the 4 weeks preceding the first administration of the study treatment\n16. Pregnant or breastfeeding women\n17. Women of childbearing potential must have a negative pregnancy test within 72 hours before starting treatment.\n18. Patients presenting hemorrhagic tumor\n19. History of allergy to red meat or tick bites or positive results of tests for IgE antibodies against cetuximab (α-1-3-galactose)\n20. Patient presenting interstitial lung disease\n21. History of organ transplant\n22. Concomitant treatment with Hypericum",{"count":373,"type":20},46,[137],"This study targets an adult population of patients with recurrent or metastatic (R\u002FM) head and neck squamous cell carcinoma (HNSCC), who have failed after a first line of treatment with pembrolizumab associated or not with chemotherapy and having an indication for a second line of treatment. Patients will be recruited in France in medical oncology departments.\n\nThe main objective is to evaluate the objective response rate of PCC in patients with HNSCC with locoregional and\u002For distant 2nd line metastatic disease after failure of pembrolizumab +\u002F- chemotherapy. The secondary objectives of the study are to evaluate other efficacy parameters by monitoring the progression of the disease, the tolerance of the treatment by collecting adverse effects and quality of life.\n\nThe duration of participation in the research is 12 months.",[77],"2025-12-17",{"date":379,"type":29},"2025-12-23",{"date":381,"type":29},"2025-01-24",{"date":383,"type":20},"2032-01",{"name":35,"class":36},5,{"id":387,"slug":4,"hasResults":10,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":10,"sex":15,"minAge":393,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":47,"phases":397,"briefSummary":398,"conditions":399,"keywords":400,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":37},"100541459","NCT06330142","Hippotherapy Teenager-pediatric Radiotherapy","T-QAP: radioTherapy eQuicie Adolescent - Pediatrics","T-QAP","Inclusion Criteria:\n\n* Children aged 8 to \\\u003C18 years.\n* With an indication for radiotherapy for cancer (of any type)\n* Patients hospitalized and\u002For managed on an ambulatory basis\n* WHO ≤ 2\n* Child and parents (or accompanying adults) who speak and understand French\n* Free, express and informed consent of the adult patient OR of those exercising parental authority for minor patients\n* Child with social security coverage\n\nExclusion Criteria:\n\n* Children afraid of horses and stables\n* Contraindication to the practice of equine-assisted therapy (allergy to horses or dust, children with asthma attacks triggered by dust\u002Fanimal hair ...)\n* Patient on stretcher\n* Children or parents (or carers) with significant cognitive impairment, making self-assessment or hetero-assessment impossible even with assistance\n* Unavailability or lack of interest in participating in equine-assisted therapy sessions","8 Years","17 Years",{"count":396,"type":20},22,[49],"This study proposes a horse-assisted therapy (HAT) approach to accompany children and young adults undergoing irradiation in the ICANS Radiotherapy Department.\n\nThe aim of this new approach is to improve quality of life and reduce anxiety in children and adolescents treated with radiotherapy. The impact of equine-assisted therapy on quality of life and anxiety disorders will be described prospectively between the start and end of irradiation in children and parents who agree to inclusion.",[54],[54,401,402,403],"Equicie","Adolescent","Pediatric",{"date":379,"type":29},{"date":406,"type":29},"2024-06-19",{"date":408,"type":20},"2027-06-19",{"name":35,"class":36},{"id":411,"slug":4,"hasResults":10,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":47,"phases":418,"briefSummary":419,"conditions":420,"keywords":423,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":37},"100602963","NCT07130344","PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer","PERPETUAL","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years at inclusion\n2. Cytological or histological confirmation of the diagnosis of low HER2 breast cancer (IHC 1+ or 2+ with non-amplified FISH\u002FSIS)\n3. Metastatic disease according to RECIST 1.1\n4. Indication of T-DXd treatment\n5. Patient (male or female of childbearing potential) using a highly effective contraceptive method\n6. Women of childbearing potential must have a negative pregnancy test within 72 hours before starting treatment\n7. Willingness and ability to comply with the visit schedule, treatment regimens, examinations and other procedures planned in the study\n8. Patient enrolled in a health insurance plan or beneficiary of such a plan\n9. Signed informed consent obtained before inclusion (after giving clear, fair and appropriate information)\n\nExclusion Criteria:\n\n1. Allergy to contrast dye\n2. Contra-indication to PET-CT\n3. Any active infection or uncontrolled intercurrent pathology\n4. Patient with a life expectancy lower than 3 months\n5. Ongoing participation in another clinical trial with an investigational treatment\n6. Pregnant or breastfeeding women\n7. Persons deprived of their freedom or under guardianship or incapable of giving consent\n8. Any psychiatric illness\u002Fsocial situation that may limit compliance with study procedures or prevent the patient from giving written informed consent",{"count":417,"type":20},262,[49],"The development of trastuzumab deruxtecan (T-DXd), an anti-HER2 conjugated antibody, has changed the therapeutic landscape of breast cancer. Anti-HER2 molecules were previously used exclusively in cases of HER2-positive breast cancer (IHC HER2 3+ or HER2 2+ with amplified FISH\u002FSISH).\n\nSince a couple of years, T-DXd is becoming a reference treatment in patients with low HER2 breast cancer (IHC 1+ or 2+ with non-amplified FISH\u002FSISH) after hormone therapy and at least one line of chemotherapy. The results of the DB04 trial revealed that T-DXd increased progression-free survival and overall survival compared to investigator's choice chemotherapy, in HER2 low breast cancers patients after one or two previous lines of chemotherapy (Modi, S. et al., 2022).\n\nIn several trials, T-DXd validation was done thanks to radiological evaluation based on conventional imaging, computed tomography scan (CT-scan) with or without contrast dye injection and bone scintigraphy.\n\n18F-Fluorodeoxyglucose positron emission tomography coupled with computed tomography (18F-FDG PET-CT) represents a major tool for diagnosis, staging, and therapeutic follow-up in oncology.\n\nIt was demonstrated that 18F-FDG PET-CT is more sensitive in detecting metastatic disease progression in HER2-positive breast cancer patients treated with trastuzumab and pertuzumab or trastuzumab and lapatinib (Ma, G. et al., 2023 et Lin, N. U. et al., 2015). Moreover, a prospective study investigated the correlation between the response rate defined by 18F-FDG PET-CT and thoraco-abdomino-pelvic CT-scan (TAP CT-scan) and the progression-free survival of patients with breast cancer. PET evaluation allowed better identification of responders versus non-responders, with a significant correlation with progression-free survival (Vogsen, M. et al., 2023).\n\nWith this study, the investigators aim to determine the role of 18F-FDG PET-CT in evaluating T-DXd treatment in patients with metastatic low HER2 breast cancer. 18F-FDG PET-CT could be an earlier evaluation tool than CT-scan in identifying non-responsive patients; and thus, avoid continuing an expensive treatment with an unfavorable toxicity profile, which could worsen both patient prognosis and quality of life.",[421,422],"Metastatic Breast Cancer","HER 2 Low-expressing Breast Cancer",[270,424,425],"18F-FDG PET-CT","T-DXd","2025-09-03",{"date":428,"type":29},"2025-09-10",{"date":430,"type":20},"2025-09",{"date":432,"type":20},"2030-09",{"name":35,"class":36},{"id":435,"slug":4,"hasResults":10,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":47,"phases":442,"briefSummary":444,"conditions":445,"keywords":446,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":37},"100605793","NCT07167134","Evolution of Hypofractionated Stereotactic Irradiation for Radio-Resistant Brain Metastases From D1-3-5 to D1-2-3","SISMIC","Inclusion Criteria:\n\n* Age \\> 18 years\n* Patients with one or more unoperated brain metastases (1-5) originating from radioresistant primary locations, including melanoma, kidney, digestive, sarcoma, and prostate \\*\n* Karnofsky Performance Status (KPS) greater than 50% (Annex 3).\n* Absence of major psychiatric conditions in the medical history that may interfere with follow-up, based on the investigator's judgement.\n* Proficiency in understanding French.\n* Signed informed consent.\n* For the ancillary study only: Patients included in the SISMIC study at centers with adequate resources and who have agreed to participate in the optional ancillary study.\n\n  * Note: Patients who have had one or more surgery for metastasis removal and also have unresectable metastases are eligible for inclusion. Irradiation of the operating bed will follow the same treatment regimen as existing metastases but will not be considered for the evaluation of local control.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* An unoperated brain metastasis whose maximum diameter is \\> 3.5 cm\n* Patients deprived of liberty or under guardianship (including curatorship).\n* Patients with a history of cerebral radiotherapy.\n* Patients with known allergy to gadolinium.\n* Contraindication to magnetic resonance imaging (MRI).",{"count":441,"type":20},264,[443],"PHASE3","The goal of this prospective, multi-center, randomized double-arm clinical trial is to demonstrate a benefit in term of local control of a shorter spread of hypofractionated stereotactic radiotherapy at D1-2-3 vs D1-3-5, in the treatment of \"radioresistant\" Brain Metastases (BM). This trial aims to recruit patients with 1 to 5 unoperated BM originating from radioresistant primary sites. Patients will be randomly assigned to either the D1-3-5 radiotherapy arm or the D1-2-3 radiotherapy arm. Stereotactic brain irradiation will be administered at a dose of 33 Gy delivered in 3 fractions.",[307],[447,448],"hypofractionated stereotactic radiotherapy","treatment duration",{"date":450,"type":29},"2025-09-11",{"date":452,"type":20},"2025-10",{"date":454,"type":20},"2030-04",{"name":35,"class":36},""]